Arginine metabolism plays a major role in cardiovascular physiology and pathophysiology, largely via nitric oxide (NO)-dependent processes. It is becoming increasingly apparent, however, that arginine metabolic enzymes other than the NO synthases can also play important roles via both NO-dependent and -independent processes. There are three sources of arginine in vivo and at least five mammalian enzymes or enzyme families that utilize arginine as substrate. Changes in arginine availability or in production of the different end products of the various arginine metabolic pathways can have distinct and profound physiologic consequences. However, our knowledge regarding the complex interplay between these pathways at the level of the whole body, specific tissues, and even individual cells, is incomplete. This review will highlight recent findings in this area that may suggest additional avenues of investigation that will allow a fuller understanding of cardiovascular physiology in health and disease.
Although a cursory survey of much of the literature on arginine metabolism over the past 15-20 years may give the impression that nitric oxide (NO) is the only product of consequence, it is important to recognize that a panoply of significant compounds are derived from arginine (Table 1 ) and that several are produced in significantly greater amounts than is NO. For example, the daily rates of creatine and urea production in healthy adults are approximately eight and 200 times, respectively, that of NO. 1 In addition to arginyl-tRNA synthetase, four sets of enzymatic activities in mammals utilize free L-arginine as substrate: nitric oxide synthase (NOS: at least three isoforms), arginase (two isoforms), arginine:glycine amidinotransferase, and arginine decarboxylase ( Figure 1 ). Although seemingly complex, the scheme depicted in this figure is simplified in that multiple isoforms of the enzymes, their localization within subcellular compartments, or identities of the multiple transporters that move arginine across the plasma or mitochondrial membranes are not indicated. Arginine, ornithine and citrulline are prominently displayed not only because they represent key intersections in arginine metabolic pathways but also because their concentrations are commonly included in amino acid analyses of plasma and serum. Because changes in circulating levels of these amino acids can readily be identified, it can be tempting to infer changes in activities of specific arginine metabolic enzymes, based solely on altered levels of specific amino acids. However, it should be apparent from Figure 1 that changes in plasma levels of individual amino acids alone are not sufficiently informative to validate such inferences conclusively.
Although there are multiple routes for catabolism of arginine, there is only one route for its synthesis, via citrulline ( Figure 1 ). Large amounts of arginine are synthesized within the urea cycle in hepatocytes, but it is immediately hydrolyzed to ornithine and urea and thus provides little or no arginine for the whole body. In adults, glutamate is the primary source of the carbon skeleton for citrulline synthesis by epithelial cells of the small intestine, but proline is the principal source of the carbon skeleton in neonates. 1, 2 Thus, the small intestine is the major source of circulating citrulline. It is produced also by the NOS and dimethyl arginine dimethylaminohydrolase (DDAH) enzymes ( Figure 1 ) but this represents a minor fraction of plasma citrulline in healthy adults. The proximal tubules of the kidney extract citrulline from the circulation and convert it to arginine, which is returned to the circulation. This metabolic collaboration between small intestine and kidney is known as the intestinalrenal axis of arginine synthesis. 1, 2 The endogenous synthesis of arginine accounts for the fact that it is not an essential dietary amino acid in healthy adults. In growing infants and children, however, or during recovery from injury or infection, endogenous synthesis may not be sufficient to meet physiologic requirements and thus arginine is classified as a conditionally essential or semi-essential amino acid. [3] [4] [5] Although the kidneys are the major site of arginine production from citrulline in adults, many cell types also have this capability, albeit to different degrees and at considerably lower levels. Consequently, some of the citrulline produced from arginine by the NOS enzymes can be recycled to arginine by argininosuccinate synthetase and argininosuccinate lyase in a pathway referred to as the citrulline-NO cycle. 1, 2, 6 Studies using cultured cells have shown that arginine recycling capacity is limiting for high-output NO synthesis by inducible NOS in vascular smooth muscle cells, 7 which may be relevant to infection or inflammatory conditions but not to vascular function under normal conditions. More recently, experiments using RNA interference indicated that expression of argininosuccinate synthetase was required not only for NO synthesis but also for viability of cultured bovine aortic endothelial cells. 8 However, it was unclear whether the reduced capacity for NO synthesis was due directly to reduced substrate availability resulting from inhibition of recycling capacity or was secondary to, for example, decreased expression of endothelial NOS or reduced availability of essential cofactors such as tetrahydrobiopterin. In any case, the contribution of the citrulline-NO cycle to NO production in the cardiovascular system in vivo remains to be established. By comparing the molar ratio of citrulline to nitrate plus nitrite produced, recycling of citrulline was apparent in cultured bovine coronary endothelial cells 9 but not in cultured rat coronary endothelial cells, 10 raising the possibility of species differences in this aspect of arginine metabolism.
Of the four arginine catabolic enzymes identified in Figure 1 , the ones whose actions most impact on (Although some interesting ideas on potential metabolic inter-relationships between arginine, creatine, homocysteine, ADMA and synthesis of NO have been proposed, 11, 12 there is little experimental information on this topic at present.) As the roles and regulation of the NOS enzymes have been amply discussed in many reviews, the following sections of this article will focus on the arginase isoforms, with emphasis on aspects most relevant to vascular biology and disease. Additional information on the arginases and other important features of arginine metabolism not discussed here may be found in recent reviews. [13] [14] [15] [16] [17] [18] [19] [20] The roles of ADMA and its degradative enzyme DDAH are considered in other articles in this issue. Two arginase isoforms are expressed in mammals: a cytosolic isoform (type I) that is abundant in liver as a component of the urea cycle and a mitochondrial isoform (type II) that is relatively abundant in kidney and prostate. These isoforms are the products of distinct genes, which in humans are located on chromosomes 6q23 (type I arginase) and 14q24 (type II arginase). 21 A modest level of arginase activity is constitutively expressed in endothelial cells, 9, 10, [22] [23] [24] and this activity is further elevated by exposure to agents such as lipopolysaccharide plus tumour necrosis factor alpha 24 or with increased age. 25 Arginine catabolism by arginase is nearly 200-fold greater than its catabolism by NOS in unstimulated rat coronary endothelial cells. 10 In nonhuman endothelial cells, the constitutive activity is due largely, if not entirely, to expression of arginase I, which is further increased in response to lipopolysaccharide. 22 Arginase II, whose expression is essentially undetectable in unstimulated endothelial cells from experimental animals but is present in unstimulated human cells, 24, 26 also can be induced in response to lipopolysaccharide, 22 but under most circumstances studied to date this isoform represents a minor fraction of total arginase activity in stimulated endothelial cells. One exception to this general picture is the recent finding that the increased arginase activity in endothelial cells from patients with pulmonary arterial hypertension is due to increased expression of arginase II, with little increase in arginase I expression. 26 Additional studies are needed to determine whether patterns of arginase expression found in endothelial cells of rodents or cattle consistently differ from patterns of expression in human cells.
Based on observations that inhibition of arginase activity results in increased endothelial NO production, 23, [25] [26] [27] [28] [29] the presence of arginase in endothelial cells apparently serves to limit the availability of substrate for NO synthesis. In conditions such as hypertension and ischemia-reperfusion, or in the vessels of older animals, endothelial arginase activity is elevated and thus can contribute to endothelial dysfunction by further reducing cellular capacity for NO synthesis. [25] [26] [27] 29 In contrast to the altered activity profile in hypertension, activities of both NOS and arginase were significantly reduced in endothelial cells of diabetic BB rats when compared with nondiabetic controls. 10 Studies using endothelial cells stably transfected to overexpress arginase I or II have revealed that arginase activity is limiting for polyamine synthesis and endothelial cell proliferation. 30 Furthermore, at least half of the ornithine generated by arginase activity in endothelial cells is converted to proline, and the rate of arginine-to-proline conversion was increased in arginase-overexpressing endothelial cells. 9 Thus, arginase may represent an important factor in supporting synthesis of collagen, a proline-rich protein, by endothelial cells or by neighboring cells in the vasculature. Some arginine-derived ornithine was converted also to glutamate and this conversion also increased in arginase-overexpressing cells, 9 but the extent of this conversion was undoubtedly underestimated because of active redistribution of the carbon skeleton into other metabolites by the transaminases in endothelial cells.
In contrast to the information available for endothelial cells, less is known about arginase in vascular smooth muscle. Arginase I is expressed in vascular smooth muscle cells and is inducible by interleukin (IL)-4, IL-13, transforming growth factor (TGF)-␤, and lysophosphatidylcholine. [31] [32] [33] Induction of arginase I by TGF-␤ resulted in increased conversion of arginine to proline and correlated with increased production of collagen I. 32 Increasing arginase I expression in primary aortic smooth muscle cells by stable transfection with an arginase I expression plasmid or by treatment with TGF-␤ or lysophosphatidylcholine resulted in greater production of polyamines [32] [33] [34] and, more importantly, in a higher proliferation rate, as measured by thymidine incorporation. 34 Inhibition of arginase resulted in reduced production of polyamines. 33 These results demonstrate that arginase activity can be limiting for proliferation of vascular smooth muscle cells and thus should be considered as a possible regulatory factor in intimal hyperplasia.
Arginase I is also expressed in human red blood cells 35 and is thus released in active form on hemolysis. Consequently, increased plasma levels of cell-free arginase are found in chronic hemolytic conditions such as sickle cell disease. [36] [37] [38] [39] Increases in circulating levels of arginase can contribute to reductions in circulating levels of arginine, as seen in sickle cell disease. [36] [37] [38] [39] [40] In turn, reduced levels of arginine can contribute to reductions in NO production, possibly resulting in vascular dysfunction, such as pulmonary hypertension. 37, 38 It is predicted that this scenario will be applicable in all chronic hemolytic disorders, but at the time of writing there is virtually no information on this point for such disorders other than sickle cell disease. Because the majority of endogenous arginine synthesis occurs in the kidney, 1 the possibility that renal dysfunction may also contribute to any reduction in plasma arginine levels in patients with hemolytic disease should always be considered. Similarly, individuals with short bowel syndrome will generate less citrulline, the precursor for renal arginine synthesis, and also experience reductions in plasma arginine levels. [41] [42] [43] Thus, arginine can become an essential dietary amino acid in patients with impaired renal or intestinal function. The release of active arginase on hemolysis also has practical implications for analyses of plasma amino acids; that is, artifactually reduced values for plasma arginine levels and increased values for plasma ornithine levels will be obtained if whole blood specimens are not promptly collected and processed prior to amino acid analysis. 44 In summary, the arginases may impact on vascular physiology by both NO-dependent and -independent mechanisms. Thus, the arginases may not only limit the availability of arginine for NO synthesis but they can also promote polyamine synthesis and cell proliferation as well as synthesis of proline and possibly collagen. Accordingly, arginase activity or expression may represent a useful therapeutic target for some cardiovascular diseases. It is clear from this brief review, however, that much remains to be learned regarding the roles and regulation of the arginases in the cardiovascular system before any such therapies can be developed.
